Stay Informed on Key Developments

Investor News and Updates

Stay informed about key developments at our company as they happen. Discover our Ad-Hoc Releases and subscribe to our newsletter to receive the latest news and topics of interest.

271 - 280of 392 News

August 20, 2019

Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars

August 08, 2019

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy

August 06, 2019

Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets

July 31, 2019

Not intended for U.S. and UK Media

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer

July 31, 2019

Not intended for U.S. and UK Media

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer

July 30, 2019

Second quarter of 2019:

Bayer on track in operational business

July 30, 2019

Second quarter of 2019:

Bayer on track in operational business

July 26, 2019

Not intended for U.S. and UK Media

Bayer receives positive CHMP opinion for precision oncology treatment larotrectinib with first ever tumor-agnostic indication in in Europe

July 22, 2019

Yellow Wood Partners to acquire iconic Dr. Scholl’s™ brand from Bayer

July 18, 2019

Not intended for U.S. and UK Media

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga™ and Opdivo™ as combination therapy in patients with colorectal cancer

Inform Yourself on Special Topics

Investor News and Updates

Control Weeds, Not Farming

Everything You Need to Know About Glyphosate

Managing Glyphosate Litigation

Managing and Mitigating PCB Litigation Risk